CoChat

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O 6 -Methylguanine–DNA Methyltransferase Biomarker Analyses

Open access
Cloughesy, Timothy, Finocchiaro, Gaetano, Belda-Iniesta, Cristóbal, Recht, Lawrence, Brandes, Alba A., Pineda, Estela, Mikkelsen, Tom, Chinot, Olivier L., Balana, Carmen, Macdonald, David R., Westphal, Manfred, Hopkins, Kirsten, Weller, Michael, Bais, Carlos, Sandmann, Thomas, Bruey, Jean-Marie, Koeppen, Hartmut, Liu, Bo, Verret, Wendy, Phan, See-Chun, Shames, David S. · 2017 · Journal of Clinical Oncology
Cited by 146

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in many countries. Aberrant MET expression has been reported in glioblastoma and may contribute to bevacizumab resistance. The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. Methods: At first recurrence after chemoradiation, bevacizumab-naïve patients with glioblastoma were randomly assigned 1:1 to receive Ona (15 mg/kg, once every 3 weeks) + Bev (15 mg/kg, once every 3 weeks) or Pla + Bev until disease progression. The primary end point was progression-free survival by response assessment in neuro-oncology criteria. Secondary end points were overall survival, objective response rate, duration of response, and safety. Exploratory biomarker analyses correlated efficacy with expression levels of MET ligand hepatocyte growth factor, O 6 -methylguanine–DNA methyltransferase promoter methylation, and glioblastoma subtype. Results: Among 129 patients enrolled (Ona + Bev, n = 64; Pla + Bev, n = 65), baseline characteristics were balanced. The median progression-free survival was 3.9 months for Ona + Bev versus 2.9 months for Pla + Bev (hazard ratio, 1.06; 95% CI, 0.72 to 1.56; P = .7444). The median overall survival was 8.8 months for Ona + Bev and 12.6 months for Pla + Bev (hazard ratio, 1.45; 95% CI, 0.88 to 2.37; P = .1389). Grade ≥ 3 adverse events were reported in 38.5% of patients who received Ona + Bev and 35.9% of patients who received Pla + Bev. Exploratory biomarker analyses suggested that patients with high expression of hepatocyte growth factor or unmethylated O 6 -methylguanine–DNA methyltransferase may benefit from Ona + Bev. Conclusion: There was no evidence of further clinical benefit with the addition of onartuzumab to bevacizumab compared with bevacizumab plus placebo in unselected patients with recurrent glioblastoma in this phase II study; however, further investigation into biomarker subgroups is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.64.7685

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 146

Metadata

Authors
Cloughesy, T., Finocchiaro, G., Belda-Iniesta, C., Recht, L., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balana, C., Macdonald, D. R., Westphal, M., Hopkins, K., Weller, M., Bais, C., Sandmann, T., Bruey, J.-M., Koeppen, H., Liu, B., Verret, W., Phan, S.-C., & Shames, D. S.
Venue
Journal of Clinical Oncology
Published
2017-01-20
Volume
35
Issue
3
Pages
343-351
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2560189464
Cited by
146
References
2
FWCI
6.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O 6 -Methylguanine–DNA Methyltransferase Biomarker Analyses. https://app.cochat.ai/papers/10.1200/jco.2015.64.7685
The paper
Cloughesy, T., Finocchiaro, G., Belda-Iniesta, C., Recht, L., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balana, C., Macdonald, D. R., Westphal, M., Hopkins, K., Weller, M., Bais, C., Sandmann, T., Bruey, J.-M., Koeppen, H., Liu, B., Verret, W., . . . Shames, D. S. (2017). Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O 6 -Methylguanine–DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.64.7685

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.